{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:46:29Z","timestamp":1791193589132,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.trim.2010.04.007","type":"journal-article","created":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T09:01:51Z","timestamp":1272704511000},"page":"93-103","source":"Crossref","is-referenced-by-count":49,"title":["Impact of different long-term maintenance immunosuppressive therapy strategies on patients' outcome after heart transplantation"],"prefix":"10.1016","volume":"23","author":[{"given":"Michael","family":"Dandel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Brendan","family":"Lehmkuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Knosalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Hetzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2010.04.007_bib1","series-title":"Primer on Transplantation. American Society of Transplantation","first-page":"87","article-title":"Principles and overview of immunosuppression","author":"Halloran","year":"2001"},{"key":"10.1016\/j.trim.2010.04.007_bib2","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1161\/01.CIR.0000150332.42276.69","article-title":"Drug therapy in the heart transplant recipient: Part II: Immunosuppressive Drugs","volume":"110","author":"Lindenfeld","year":"2004","journal-title":"Circulation"},{"issue":"7 Suppl","key":"10.1016\/j.trim.2010.04.007_bib3","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/TP.0b013e318169c380","article-title":"Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome","volume":"85","author":"Mourad","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.04.007_bib4","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.healun.2006.06.010","article-title":"Myocophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: Analysis of the Transplant Registry of the ISHLT","volume":"25","author":"O'Neill","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.healun.2007.08.010","article-title":"Influence of induction therapy immunosuppressive regimen and ant-viral prophylaxis on development of lymphomas after heart transplantation: Data from the Spanish Post-Heart Transplant Tumor Registry","volume":"26","author":"Crespo-Leiro","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib6","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.healun.2008.06.017","article-title":"Registry of the International Society for Heart and Lung Transplantation: 25th official adult heart transplant report:2008","volume":"27","author":"Taylor","year":"2008","journal-title":"J Heart Lung Transplant"},{"issue":"9","key":"10.1016\/j.trim.2010.04.007_bib7","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.healun.2004.08.003","article-title":"Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation","volume":"24","author":"Rosenberg","year":"2005","journal-title":"J Heart Lung Transplant"},{"issue":"26","key":"10.1016\/j.trim.2010.04.007_bib8","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1056\/NEJMoa032953","article-title":"Daclizumab to prevent rejection after heart transplantation","volume":"352","author":"Hersberger","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.trim.2010.04.007_bib9","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.healun.2006.09.002","article-title":"Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation","volume":"25","author":"Flaman","year":"2006","journal-title":"J Heart Transplant"},{"issue":"11","key":"10.1016\/j.trim.2010.04.007_bib10","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/01.tp.0000209924.00229.e5","article-title":"A randomized multicenter comparison of basiliximab and muronomab (OKT3) in heart transplantation: SIMCOR study","volume":"81","author":"Segovia","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.04.007_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.healun.2008.02.016","article-title":"Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin","volume":"27","author":"Zhang","year":"2008","journal-title":"J Heart Lung Transplant"},{"issue":"7","key":"10.1016\/j.trim.2010.04.007_bib12","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.transproceed.2007.06.073","article-title":"Two-dose daclizumab, tacrolimus, mycophenolate mofetil and steroid free regimen in de novo cardiac recipients: early experience","volume":"39","author":"Mastrobuoni","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trim.2010.04.007_bib13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1600-6143.2006.01633.x","article-title":"Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology","volume":"7","author":"Nankivell","year":"2007","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.trim.2010.04.007_bib14","first-page":"775","article-title":"European Multicenter Tacrolimus (FK506) Heart Pilot Study: one year results\u2014European Tacrolimus Multicenter Heart Study Group","volume":"17","author":"Reichart","year":"1998","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.trim.2010.04.007_bib15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1053-2498(98)00060-6","article-title":"A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus","volume":"18","author":"Taylor","year":"1999","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib16","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/j.1600-6143.2006.01300.x","article-title":"Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients \u2013 a large European trial","volume":"6","author":"Grimm","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jacc.2008.05.020","article-title":"The changing face of heart transplantation","volume":"52","author":"Hunt","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trim.2010.04.007_bib18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.healun.2006.02.003","article-title":"Long-term results of tacrolimus monotherapy in cardiac transplant recipients","volume":"25","author":"Lubitz","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.healun.2005.02.002","article-title":"Keogh, Bourge R, Renlund D, Mentzer R. et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients","volume":"24","author":"Eisen","year":"2005","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"10.1016\/j.trim.2010.04.007_bib20","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.transproceed.2009.06.031","article-title":"Maintenance immuno-suppression with mycophenolate mofetil:Long-term efficacy and safety","volume":"41","author":"Dandel","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trim.2010.04.007_bib21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.healun.2006.01.003","article-title":"Preventing cardiac allograft vasculopathy: Long-term beneficial effects of mycophenolate mofetil","volume":"25","author":"Kaczmarek","year":"2006","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.trim.2010.04.007_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00007890-199808270-00016","article-title":"A randomized active-controlled trial of myocophenolate mofetil in heart transplant recipients. Myocophenolate Mofetil Investigators","volume":"66","author":"Kobashigawa","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.04.007_bib23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.tp.0000253883.52525.7c","article-title":"Myocophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplanted patients","volume":"83","author":"Hamour","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.04.007_bib24","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/01.TP.0000153302.27299.16","article-title":"Long-term benefits of mycophenolate mofetil after heart transplantation","volume":"79","author":"Keogh","year":"2005","journal-title":"Transplantation"},{"issue":"S 02","key":"10.1016\/j.trim.2010.04.007_bib25","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1055\/s-2008-1039259","article-title":"Immunosuppression and Long-Term Outcome after Heart Transplantation","volume":"57","author":"Dandel","year":"2009","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1016\/j.trim.2010.04.007_bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01.TP.0000129814.52456.25","article-title":"Tacrolimus or cyclosporine: Which is the better partner or mycophenolate mofetil in heart transplant recipients","volume":"78","author":"Meiser","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.04.007_bib27","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1097\/01.TP.0000153301.27572.B2","article-title":"From mechanisms to long-term benefits","volume":"79","author":"Mamelok","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.04.007_bib28","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1600-6143.2006.01297.x","article-title":"Myocophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: Reanalysis of the multicenter trial","volume":"6","author":"Kobashigawa","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib29","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.107.711911","article-title":"Cardiac allograft vasculopathy. Recent developments","volume":"117","author":"Schmauss","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.trim.2010.04.007_bib30","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for prevention of allograft rejection and vasculopathy in cardiac transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.trim.2010.04.007_bib31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.healun.2007.03.005","article-title":"Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplant recipients: A 24 month analysis","volume":"26","author":"Vigano","year":"2007","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.trim.2010.04.007_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.healun.2009.08.018","article-title":"Changing trends in infectious disease in heart transplantation","volume":"29","author":"Haddad","year":"2010","journal-title":"Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib33","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1016\/j.transproceed.2005.09.155","article-title":"Calcineurin inhibitors in heart transplantation","volume":"37","author":"Crespo-Leiro","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trim.2010.04.007_bib34","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/00007890-200111270-00015","article-title":"Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: An analysis of the joint UNOS\/ISHLT Thoracic Registry","volume":"72","author":"Hosenpud","year":"2001","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.trim.2010.04.007_bib35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.healun.2008.10.004","article-title":"Tacrolimus vs. cyclosporine microemulsions for heart transplant recipients: a meta-analysis","volume":"28","author":"Ye","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib36","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1600-6143.2006.01290.x","article-title":"Tacrolimus with myocophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1 year report","volume":"6","author":"Kobashigawa","year":"2006","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.trim.2010.04.007_bib37","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1097\/01.tp.0000290686.68910.bd","article-title":"A lower incidence of cytomegalovirus in de novo heart transplant recipients randomized to everolimus","volume":"84","author":"Hill","year":"2007","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.trim.2010.04.007_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1432-2277.2008.00771.x","article-title":"Calcineurin-inhibitor minimization after heart transplantation","volume":"22","author":"Zuckermann","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.trim.2010.04.007_bib39","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.healun.2007.02.008","article-title":"Observational study with Everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients","volume":"26","author":"Lehmkuhl","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib40","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1161\/CIRCULATIONAHA.107.692996","article-title":"Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation","volume":"116","author":"Raichlin","year":"2007","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.trim.2010.04.007_bib41","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/MOT.0b013e32830fdf70","article-title":"Proliferation signal inhibitors and cardiac vasculopathy","volume":"13","author":"Raichlin","year":"2008","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib42","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1600-6143.2006.01282.x","article-title":"Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients","volume":"6","author":"Kupahally","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib43","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a non-renal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trim.2010.04.007_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0012.2007.00739.x","article-title":"Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity","volume":"22","author":"Flechner","year":"2008","journal-title":"Clin Transpl"},{"issue":"6","key":"10.1016\/j.trim.2010.04.007_bib45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.healun.2007.03.010","article-title":"Is there a role for proliferation signal\/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology","volume":"26","author":"Valantine","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib46","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.transproceed.2004.10.062","article-title":"Initial experience with sirolimus and mucophenolate mofetil for renal rescue from cyclosporine nephrotoxicitys after heart transplantation","volume":"36","author":"Lyster","year":"2004","journal-title":"Tranplant Proc"},{"issue":"5","key":"10.1016\/j.trim.2010.04.007_bib47","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/01.tp.0000177644.45192.a3","article-title":"Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the mid-term follow-up","volume":"81","author":"Bestetti","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.04.007_bib48","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.healun.2007.08.014","article-title":"Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation","volume":"27","author":"Zuckermann","year":"2008","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.trim.2010.04.007_bib49","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0041-1345(03)00360-9","article-title":"Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine","volume":"35","author":"Baryalei","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trim.2010.04.007_bib50","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.trim.2006.02.001","article-title":"Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients","volume":"16","author":"Schweiger","year":"2006","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trim.2010.04.007_bib51","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.ehj.2004.06.032","article-title":"Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients.- The IMPROVED multi-center study","volume":"25","author":"St\u00f6rk","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.trim.2010.04.007_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1053-2498(00)00296-5","article-title":"Benefit of mycophenolate mophetil (MMF) in patients with cyclosporine (CYA) induced nephropathy after cardiac transplantation","volume":"20","author":"Zuckermann","year":"2001","journal-title":"J Heart Lung Transplant Int"},{"key":"10.1016\/j.trim.2010.04.007_bib53","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","article-title":"Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients","volume":"5","author":"Vitko","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib54","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1016\/j.transproceed.2006.08.034","article-title":"Do cardiovascular risk factors influence cardiac allograft vasculopathy?","volume":"38","author":"Chamorro","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trim.2010.04.007_bib55","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.healun.2006.05.001","article-title":"Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients","volume":"25","author":"Kobashigawa","year":"2006","journal-title":"J Heart Lung Transplant"},{"issue":"Suppl 3A","key":"10.1016\/j.trim.2010.04.007_bib56","first-page":"143S","article-title":"Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients","volume":"35","author":"Abdel-Fattah","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trim.2010.04.007_bib57","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.healun.2005.11.452","article-title":"Five-year results of a randomized, single-center study of tacrolimus vs. microemulsion cyclosporine in heart transplant patients","volume":"25","author":"Kobashigawa","year":"2006","journal-title":"J Heart Lung Transplant"},{"issue":"11","key":"10.1016\/j.trim.2010.04.007_bib58","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00002512-200724110-00004","article-title":"Immunosuppressive Therapy in older cardiac transplant patients","volume":"24","author":"Aliabadi","year":"2007","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.trim.2010.04.007_bib59","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.healun.2008.01.018","article-title":"Hypertension after pediatric heart transplantation is primarily associated with immunosuppressive regimen","volume":"27","author":"Roche","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib60","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1097\/00007890-200004270-00012","article-title":"Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine","volume":"69","author":"Aleksic","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.04.007_bib61","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1053-2498(02)00422-9","article-title":"Reversal of chronic cyclosporine nephrotoxicity after heart transplantation \u2013 Potential role of mycophenolate mofetil","volume":"21","author":"Tedoriya","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib62","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1016\/j.transproceed.2004.09.035","article-title":"Chronic cyclosporine-induced nephrotoxicity in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine","volume":"36","author":"Sanchez","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trim.2010.04.007_bib63","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/01.TP.0000156990.11135.60","article-title":"Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil","volume":"79","author":"Boyer","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.04.007_bib64","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1399-0012.2005.00238.x","article-title":"Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule","volume":"19","author":"Manito","year":"2005","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trim.2010.04.007_bib65","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1440-1797.2006.00548.x","article-title":"Preliminary experience with mycophenolate mophetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity","volume":"11","author":"Al-Aly","year":"2006","journal-title":"Nephrology"},{"key":"10.1016\/j.trim.2010.04.007_bib66","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/HCO.0b013e32801466e4","article-title":"Renal protective strategies in heart transplant patients","volume":"22","author":"Cantarovich","year":"2007","journal-title":"Curr Opin Cardiol"},{"issue":"5","key":"10.1016\/j.trim.2010.04.007_bib67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.healun.2007.11.565","article-title":"Cyclosporine reduction in the presence of everolimus: 3 months data from a Canadian pilot study of maintenance cardiac allograft recipients","volume":"27","author":"Ross","year":"2008","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.trim.2010.04.007_bib68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1432-2277.2009.00940.x","article-title":"Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study","volume":"23","author":"Ross","year":"2010","journal-title":"Transpl Int"},{"issue":"7","key":"10.1016\/j.trim.2010.04.007_bib69","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/TP.0b013e3181cbac2d","article-title":"Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction : a multicenter randomized trial","volume":"89","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.04.007_bib70","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.healun.2007.03.011","article-title":"Low-dose tacrolimus\/sirolimus withdrawal in heart recipients is highly efficacious","volume":"26","author":"Meiser","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib71","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/TP.0b013e3181aacd22","article-title":"Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients","volume":"88","author":"Lehmkuhl","year":"2009","journal-title":"Transplantation"},{"issue":"1\u20132","key":"10.1016\/j.trim.2010.04.007_bib72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.trim.2008.10.001","article-title":"Minimization of immunosuppression: transplant immunology","volume":"20","author":"Patel","year":"2008","journal-title":"Transpl Immunol"},{"issue":"10","key":"10.1016\/j.trim.2010.04.007_bib73","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2165\/00003495-200868100-00004","article-title":"Calcineurin inhibitor sparing in paediatric solid organ Transplantation: managing the efficacy\/toxicity conundrum","volume":"68","author":"Tredger","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.trim.2010.04.007_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.healun.2010.01.005","article-title":"Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation","author":"Gude","year":"2010","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.trim.2010.04.007_bib75","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.TP.0000103740.98095.14","article-title":"Mycophenolate mofetil and sirolimus as calcineurin-inhibitor free immunosuppression for late cardiac transplant recipients with chronic renal failure","volume":"77","author":"Groetzner","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.04.007_bib76","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.healun.2005.08.015","article-title":"Sirolimus in cardiac transplantation: use as a primary immunosuppressant in cacineurin-induced nephrotoxicity","volume":"24","author":"Kushwaha","year":"2005","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.trim.2010.04.007_bib77","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/TP.0b013e3181963371","article-title":"Mycophenolate and sirolimus as CNI-free immunosuppression improves renal function better than CNI-reduction in late cardiac transplant recipients with chronic heart failure","volume":"87","author":"Groetzner","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2010.04.007_bib78","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.healun.2007.01.010","article-title":"Recommendations for the use of everolimus (Certican) in heart transplantation: Results from the second German-Austrian Certican Consensus Conference","volume":"26","author":"Rothenburger","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib79","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1600-6143.2005.00757.x","article-title":"First experience with de novo calcineurin-inhibitor-free immunosuppression following heart transplantation","volume":"1","author":"Meiser","year":"2005","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.trim.2010.04.007_bib80","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-6143.2008.02456.x","article-title":"Outcomes following de novo CNI-free immunosuppression after heart transplantation: A single center experience","volume":"9","author":"Leet","year":"2009","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.trim.2010.04.007_bib81","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.healun.2008.01.018","article-title":"Hypertension after pediatric heart transplantation is primarily associated with immunosuppressive regimen","volume":"27","author":"Roche","year":"2008","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"10.1016\/j.trim.2010.04.007_bib82","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.transproceed.2009.06.081","article-title":"Steroid use in transplant patients in Spain in the current era: A multcenter Survey","volume":"41","author":"Crespo-Leiro","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trim.2010.04.007_bib83","first-page":"428","article-title":"Initial success of steroid weaning late after heart transplantation","volume":"11","author":"Kobashigawa","year":"1992","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib84","first-page":"431","article-title":"Successful withdrawal of corticosteroids in heart transplantation","volume":"11","author":"Miller","year":"1992","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib85","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1053-2498(00)00080-2","article-title":"Long-term follow-up of pediatric cardiac transplant recipients on a steroid-free regime: role of endomyocardial biopsy","volume":"19","author":"Leonard","year":"2000","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib86","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1034\/j.1399-3046.2003.00014.x","article-title":"Pediatric cardiac transplant: results using a steroid-free maintenance regimen","volume":"7","author":"Leonard","year":"2003","journal-title":"Pediat Transplant"},{"issue":"5","key":"10.1016\/j.trim.2010.04.007_bib87","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.healun.2009.11.601","article-title":"Safety and early outcomes using corticosteroid-avoidance immunosuppression protocol in pediatric heart transplant recipients","volume":"29","author":"Singh","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trim.2010.04.007_bib88","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1399-0012.2007.00748.x","article-title":"Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study","volume":"22","author":"Yamani","year":"2008","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trim.2010.04.007_bib89","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.0000136812.90177.94","article-title":"Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease","volume":"110","author":"Keogh","year":"2004","journal-title":"Circulation"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327410000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327410000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T10:01:05Z","timestamp":1711447265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327410000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0966327410000298"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2010.04.007","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}